February 12, 2015 | The Israeli biomedical company RedHill Biopharma raised $12.5 million in its initial public offering on NASDAQ. The offering was led by Wells Fargo Securities along with Roth Capital Partners and MLV & Co. The offering price ran at $12.5 per share for each American Depository Share, which represents ten ordinary shares. RedHill specializes in the development of drug delivery methods as well as combinations of existing drug-types. The company’s most popular drug types are for the treatment of Chrohn’s disease and for the nausea associated with chemotherapy.